The nationwide recall of the emergency drug follows a July recall of 4 lots of Adequan injections by the company's animal health division after glass fibers were detected.
|Articles|February 16, 2022
Jaguar Animal Health seeks MUMS designation from FDA to expand canine diarrhea treatment
Advertisement
Jaguar Animal Health has submitted a request to the FDA’s Center for Veterinary Medicine for Minor Use/Minor Species (MUMS) designation for the company's drug candidate crofelemer (Canalevia) for treatment of exercise-induced diarrhea (EID) in dogs. The oral, plant-based drug was conditionally approved by the FDA in December 2021 for the treatment of chemotherapy-induced diarrhea (CID) in dogs.
"MUMS designation is a status similar to ‘orphan drug' status for human drugs, and it makes the proposed intended use of a MUMS drug eligible for specific incentives supporting product approval or conditional approval," said Michael Guy, DVM, MS, PhD, Jaguar Health's vice president of preclinical and nonclinical studies, in a company press release.
Receipt of MUMS designation for crofelemer for EID in dogs provide the company with eligibility to apply for federal grants related to development costs, and allow Jaguar Animal Health with a longer period—7 years—of marketing exclusivity following conditional approval of the drug for EID in dogs, according to Guy. Under the brand name Canalevia-CA1, crofelemer previously received MUMS designation for CID in dogs.
Advertisement
“We believe [Crofelemer] also meets the requirements for MUMS designation for our planned EID indication in dogs," said Guy in the release.
Jaguar Animal Health is anticipating conditional approval from the FDA for crofelemer, under the brand name Canalevia-CA2, for treatment of EID in dogs in the fourth quarter of 2022.
Crofelemer is should only be used by or on the order of licensed veterinarians. The most reported adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Reference
Jaguar Animal Health seeks MUMS designation from FDA for Canalevia (Crofelemer) for treatment of exercise-induced diarrhea (EID) in dogs. News release. Jaguar Animal Health. February 16, 2022. Accessed February 16, 2022.
Advertisement
Related to this article
Preclinical testing at The Ohio State University found Telomir-Zn inhibited growth of canine and human osteosarcoma cell lines, prompting the company to explore a possible in-vivo study in dogs with naturally occurring tumors.
Caroline Cox, LSW, MSW, and Erika Krick, VMD, DACVIM (Oncology), discuss the role of veterinary social workers in supporting clients, communicating with veterinary teams, and helping practices address the human side of veterinary care in this Q&A from an interview at the 2026 Fetch National Harbor Veterinary Conference.
Two notable pet-industry acquisitions closed in September. One bringing AI-powered clinical documentation into IDEXX's software ecosystem, the other marking the first acquisition for fresh-food brand The Farmer's Dog.
New leadership moves, recognition, and achievement.
In a slideshow drawn from an on-site dvm360 interview at the 2026 Fetch National Harbor Veterinary Conference, a veterinary oncologist and a veterinary social worker walk through how the role supports owners and staff across a pet's cancer diagnosis, treatment, and end-of-life care.
Caitlyn Getty, DVM, PhD, DACVIM (Nutrition), explains how synergistic prebiotic fiber blends outperform single supplements in supporting fermentation, postbiotics, and gut health.
New leadership moves, recognitions, and achievements.
Advertisement
Advertisement
Trending on dvm360
1
Natural Bridge Wildlife Ranch welcomes third southern white rhino calf in 3 years
2
Experimental drug found to slow bone cancer cell growth in dog and human lab tests
3
Q&A: Caregiver burden can begin early in pet illness. Are veterinary teams equipped to support clients, and how can veterinary social workers help both parties?
4
Chasing conservation: Forging a path to a career in zoo medicine
5